ES2045276T3 - Preparacion de insulina - Google Patents

Preparacion de insulina

Info

Publication number
ES2045276T3
ES2045276T3 ES89112310T ES89112310T ES2045276T3 ES 2045276 T3 ES2045276 T3 ES 2045276T3 ES 89112310 T ES89112310 T ES 89112310T ES 89112310 T ES89112310 T ES 89112310T ES 2045276 T3 ES2045276 T3 ES 2045276T3
Authority
ES
Spain
Prior art keywords
insulin preparation
administered
insulin
biodisponibilida
torrent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89112310T
Other languages
English (en)
Inventor
Leroy Arthur Campfield
Alberto Davidovich
Martin Howard Infeld
Navnit Shah
Francoise Jeanne Smith
Joel Unowsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2045276T3 publication Critical patent/ES2045276T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA ABSORCION EN EL TORRENTE SANGUINEO Y LA BIODISPONIBILIDA DE LA INSULINA ADMINISTRADA NO PARENTERALMENTE ES SIGNIFICATIVAMENTE REALIZADA EN PRESENCIA DE UNA CANTIDAD COADMINISTRADA DE UN ESTER GLICERIDO DE ACIDO CARBOXILICO POLIOXIETILENO GLICOL-C6 A C18.
ES89112310T 1988-07-21 1989-07-06 Preparacion de insulina Expired - Lifetime ES2045276T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22268288A 1988-07-21 1988-07-21

Publications (1)

Publication Number Publication Date
ES2045276T3 true ES2045276T3 (es) 1994-01-16

Family

ID=22833245

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89112310T Expired - Lifetime ES2045276T3 (es) 1988-07-21 1989-07-06 Preparacion de insulina

Country Status (5)

Country Link
EP (1) EP0351651B1 (es)
JP (1) JPH0273021A (es)
AT (1) ATE94404T1 (es)
DE (1) DE68909135T2 (es)
ES (1) ES2045276T3 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2062227T3 (es) * 1989-08-21 1994-12-16 Hoffmann La Roche Composiciones farmaceuticas no parenterales para la insulina.
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
EP0533938A4 (en) * 1991-02-19 1993-06-16 Tsumura & Co. Composition for rectal administration of difficultly absorbable peptide
CA2145763A1 (en) * 1992-10-02 1994-04-14 William J. Curatolo Pharmaceutical compositions containing nonionic surfactants
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
JP2002531518A (ja) * 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
US20050063940A1 (en) * 2002-02-25 2005-03-24 Sveinbjorn Gizurarson Bioadhesive agent
US6855332B2 (en) 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
NZ588603A (en) 2008-03-26 2012-03-30 Oramed Ltd Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
US20110046053A1 (en) 2008-05-05 2011-02-24 Oramed Ltd. Methods and compositions for oral administration of exenatide
HUP0900482A2 (en) 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
EP3260131A1 (en) * 2012-01-03 2017-12-27 Oramed Ltd. Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes
CN113769074A (zh) 2012-02-01 2021-12-10 奥拉姆德有限公司 含有蛋白酶抑制物的组合物、包含前者的组合物和用于产生和使用前者的方法
WO2014106846A2 (en) 2013-01-03 2014-07-10 Oramed Ltd. Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof
ES2907867T3 (es) 2016-06-20 2022-04-26 Capretto Ehf Formulación estable de lípidos antimicrobianos

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1554157A (en) * 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition

Also Published As

Publication number Publication date
DE68909135D1 (de) 1993-10-21
DE68909135T2 (de) 1994-04-07
ATE94404T1 (de) 1993-10-15
EP0351651A3 (en) 1990-10-10
EP0351651A2 (en) 1990-01-24
EP0351651B1 (en) 1993-09-15
JPH0273021A (ja) 1990-03-13

Similar Documents

Publication Publication Date Title
ES2045276T3 (es) Preparacion de insulina
AU1811788A (en) Promotion of healing of meniscal tissue
ES2061772T3 (es) Inhalante aerosol que comprende un ester de retinol y/o de acido retinico.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
ATE135231T1 (de) Verwendung von ''cartilage-inducing factor'' (cif) zur behandlung von hemato- oder lymphopoietischen krankheiten
GB8804164D0 (en) Bandage for administering physiologically active compound
DE3876143D1 (de) Wegwerfbare infusionskassette mit pumpenkammer sowie triebwerk dafuer.
AU3073789A (en) Drug delivery using pulmonary surfactant to facilitate absorption
AU1352188A (en) Mixtures for treating hypercholesterolemia
FI970747A0 (fi) Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa
NO173279C (no) Fremgangsm}te for fremstilling av et stabilt zink-protamin-alfa-interferonkompleks
EP0253887A1 (en) Low dosage of interferon to enhance vaccine efficiency.
WO1989007939A3 (en) Coumarins to inhibit reverse transcriptase in humans
ZA879173B (en) Therapeutic agents
DE68918331D1 (de) Menschlicher kristallinischer Granulocyt-Koloniestimulierungsfaktor und dessen Herstellung.
ATE161714T1 (de) Verwendung von gnrh, lhrh oder ihre derivate enthaltende zubereitungen mit verzögerter wirkstofffreisetzung
ES2026304A6 (es) Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
YU221889A (en) Process for producing new pharmaceutical mixture
DE69013557D1 (de) An Liposome gekuppelte bioaktive Verbindungen und ihre Verwendung in pharmazeutischen Zubereitungen.
ZA883744B (en) Promotion of healing of meniscal tissue
GR3004253T3 (es)
SE8204873D0 (sv) Farmaceutiska preparat, innefattande humant insulin och human c-peptid
ATE116849T1 (de) Pharmazeutische verwendung von fettsäuren.
USD323030S (en) Medical syringe for administering subcutaneous injections
MY100483A (en) Niflumic acid morpholinoethyl ester diniflumate, preparation, use in therapeutics as analgesic and anti- inflammatory

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 351651

Country of ref document: ES